{
    "organizations": [],
    "uuid": "65f5ff510d296a0b7fbae6ca7c526aeec43403dc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pledpharma-updates-on-pledox-phase/brief-pledpharma-updates-on-pledox-phase-i-study-in-japan-idUSFWN1PY1RQ",
    "ord_in_thread": 0,
    "title": "BRIEF-PledPharma Updates On Pledox Phase I Study In Japan",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 9 (Reuters) - Pledpharma Ab (Publ):\n* PLEDOX® SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE IN THE SUNCIST PHASE I STUDY IN JAPANESE SUBJECTS\n* ‍PLEDOX® SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE IN SUNCIST PHASE I STUDY IN JAPANESE SUBJECTS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-09T14:46:00.000+02:00",
    "crawled": "2018-02-10T14:00:43.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "pledpharma",
        "ab",
        "publ",
        "show",
        "favorable",
        "safety",
        "tolerability",
        "profile",
        "suncist",
        "phase",
        "study",
        "japanese",
        "subject",
        "show",
        "favorable",
        "safety",
        "tolerability",
        "profile",
        "suncist",
        "phase",
        "study",
        "japanese",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}